Clofazimine is under clinical development by MannKind and currently in Phase I for Mycobacterium Infections. According to GlobalData, Phase I drugs for Mycobacterium Infections have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Clofazimine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Clofazimine overview

Clofazimine (QRM-003) is under development for the treatment of pulmonary nontuberculous mycobacterial lung infections. It is a reformulated drug candidate. It is administered through inhalation route as a suspension. It acts by targeting DNA.

MannKind overview

MannKind is a biopharmaceutical company that develops and commercializes inhaled therapeutic products for patients suffering from diabetes and pulmonary arterial hypertension. Its flagship product, Afrezza is a rapid-action inhaled insulin used to control high blood sugar in adults with type 1 and type-2 diabetes. It consists of a dry powder formulation of human insulin delivered from small and portable inhaler. The company develops products based on its proprietary Technosphere formulation technology. MannKind has manufacturing facility in Danbury, Connecticut and sells product to wholesale distributors and specialty pharmacies in the US. MannKind is headquartered in Westlake Village, California, the US.

For a complete picture of Clofazimine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.